N
DMK

Natixis’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Natixis’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-551
Closed -$42K – 1291
2021
Q2 		$42K Buy
+551
New +$33.6K ﹤0.01% 843

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return

Natixis's DMK Position: Q3 2021 in Review

Natixis sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2021, closing a stake of 551 shares — an estimated $42K sold.

Natixis first reported a position in DMK in Q2 2021 and held it in 1 quarter. The position peaked at $42K in Q2 2021. 52 funds tracked by Wall St. Rank hold DMK as of Q3 2021.

  • Natixis reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Natixis sold 551 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2021, an estimated $42K.
  • Natixis first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2021 and held it in 1 quarter.
  • Natixis's DMK Pharmaceuticals Corporation Common Stock position peaked at $42K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2021.

Based on Natixis's 13F filing for Q3 2021, filed 12 Nov 2021.